Global Liposomes Market Size To Worth USD 12.48 Billion By 2033 | CAGR of 5.94%
Category: HealthcareGlobal Liposomes Market Size To Worth USD 12.48 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Liposomes Market Size is Expected to Grow from USD 7.01 Billion in 2023 to USD 12.48 Billion By 2033, at a CAGR of 5.94% during the Forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 250 pages with116 Market data tables and figures & charts from the report on the "Global Liposomes Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Stealth Liposomes, Conventional Liposomes, Cationic Liposomes, and Others), By Applications (Cosmetics, Drug Delivery, Food and Beverages, Gene Delivery, and Others), By End-User (Cosmetics Industry, Pharmaceutical and Biotechnology Companies, Research Institutes, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/liposomes-market
The liposomes market focuses on the formulation and application of liposomes for encapsulating active pharmaceutical ingredients to improve the stability and therapeutic efficacy of medications used in managing acute and chronic diseases. Liposomes are spherical artificial membranes with phospholipid bilayers, known for their membrane-like properties, biocompatibility, stability, and selectivity. They are approved by the FDA for disease treatment and diagnostic applications and can be administered via various routes. The rising prevalence of chronic diseases like cardiovascular, cancer, and diabetes has led to the need for innovative treatment approaches, such as liposomal-based treatment. Liposomes can retain medications with various physical and chemical properties, making them an excellent option for drug delivery and cancer treatment in nanomedicine. Government initiatives, such as the National Nanotechnology Initiative (NNI), support the growth of the liposomes market, enhancing interagency coordination and establishing shared goals, priorities, and strategies. Liposomes, resembling cell plasma membranes, are safe drug delivery systems suitable for lipophilic and hydrophilic drugs. They can encapsulate gases like nitric oxide for treating pulmonary hypertension. The growing use of liposomes in disease management is fueling market expansion, as they reduce systemic side effects, increase maximum-tolerated doses, and improve therapeutic benefits. However, increased expenditures of its formulation method might restrain the growth of the market.
The conventional liposomes segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the product type, the global liposomes market is categorized as stealth liposomes, conventional liposomes, cationic liposomes, and others. Among these, the conventional liposomes segment held the largest share in 2023 and is predicted to grow at a significant CAGR during the predicted period. This is attributed to its non-toxic, enhanced pharmacokinetic effects, non-immunogenic properties, safety, stability, efficient encapsulation, improved drug delivery, and ability to carry hydrophilic and lipophilic drugs.
The drug delivery segment accounted for the highest market share of 85.27% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the applications, the global liposomes market is categorized as cosmetics, drug delivery, food and beverages, gene delivery, and others. Among these, the drug delivery segment accounted for the highest market share of 85.27% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The growth of the segment is attributed to targeted drug delivery, minimizing side effects, adaptability, drug stability, and treatment intensity, particularly effective for cancerous drugs, enhancing their therapeutic activity.
The pharmaceutical and biotechnology companies segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the end-user, the global liposomes market is categorized as the cosmetics industry, pharmaceutical and biotechnology companies, research institutes, and others. Among these, the pharmaceutical and biotechnology companies segment accounted for the highest market share in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The sector is expanding due to the growing demand for novel drug delivery systems, chronic diseases, complex treatment results, liposomal formulations, molecular studies, and clinical trials.
North America is expected to hold the greatest share of the global liposomes market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global liposomes market over the forecast period. This is ascribed to its expanding healthcare infrastructure and rising chronic illnesses. Innovative medication delivery methods like liposomes are in high demand, driven by US investments in biotechnology and nanotechnology. New developments in material sciences and nanotechnology have enabled the development of more specialized and effective liposomal compositions. Liposomes are also popular in the food and beverage industry for their ability to supply nutrients and prolong shelf life, further driving market growth in North America.
Asia Pacific is predicted to grow at the fastest CAGR rate throughout the estimated period. The rise in liposomal formulations in China and India is attributed to the growth of pharmaceutical and cosmetics companies, higher healthcare costs, and the need for efficient treatments in middle-class communities. The region's growing cosmetics industry, focusing on innovation and product distinctiveness, supports this trend.
Major key players in the global liposomes market are Virpax Pharmaceuticals, Gilead Sciences, Inc., Azaya Therapeutics, Nanovex Biotechnologies SL, Avanti Polar Lipids Inc., Ipsen Biopharmaceuticals, Inc., S.G. Biopharma Pvt. Ltd., Taiwan Liposome Company Ltd., FujiFilm Holdings Corporation, Synpac Kingdom Pharmaceutical Co., Ltd., Novartis AG, Pacira BioSciences, Inc., Encapsula Nano Sciences, Precision NanoSystems Inc., and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In February 2025, Innocan Pharma Corporation was granted a patent in India for its synthetic Cannabidiol-loaded Liposome Injection Platform (LPT-CBD), a prolonged-release pharmaceutical formulation that uses liposomes to encapsulate cannabinoids. The patent protects Innocan's LPT-CBD, which has received positive feedback from the FDA for its potential use as a non-opioid alternative for chronic pain management.
- In October 2024, Lipella Pharmaceuticals received a US Patent and Trademark Office (USPTO) notice of allowance for its proprietary liposomal drug delivery platform. The patent application, titled "Delivery of Agents Using Metastable Liposomes," covers Lipella's platform technology for delivering therapeutic agents via liposome-based vehicles. The patent allows claims for Lipella's method for using metastable liposomes to deliver various therapeutic agents, including its lead assets, LP-10 and LP-310. This technology improves the safety and efficacy of treatments in oncology, cancer survivorship, and immunotherapy.
- In August 2024, Lupin launched Doxorubicin Hydrochloride Liposome Injections 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the US, following approval from the US FDA for its ANDA by Lupin's alliance partner, ForDoz Pharma Corporation, USA. This generic equivalent of Doxil® (Liposomal) is used for treating Ovarian Cancer, AIDS-related Kaposi's Sarcoma, and Multiple Myeloma.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global liposomes market based on the below-mentioned segments:
Global Liposomes Market, By Product Type
- Stealth Liposomes
- Conventional Liposomes
- Cationic Liposomes
- Others
Global Liposomes Market, By Applications
- Cosmetics
- Drug Delivery
- Food and Beverages
- Gene Delivery
- Others
Global Liposomes Market, By End-User
- Cosmetics Industry
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
Global Liposomes Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?